A Phase 4 interventional study of Sitagliptin and Glibenclamide in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 130th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2015, is one of 68 in phase 4, and was the 154th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 13 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 122nd largest by enrollment of the 170 interventional ones that give a count, is one of 7 that started in 2015, is one of 6 in phase 4, and was the 166th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that treatment with sitagliptin will be superior to treatment with glibenclamide in the change from baseline in mean amplitude of glycemic excursions (MAGE) through continuous glucose monitoring (CGM) after 13 days of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
Drug: Sitagliptin
Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
Drug: Glibenclamide
Sitagliptin 50 mg orally once a day before breakfast for 14 days
Also known as: MK-0431
Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13
MAGE is a popular metric for assessment of major (e.g., postprandial) glucose swings. MAGE is calculated as the average of differences between consecutive glucose peaks and nadirs greater than 1 standard deviation (SD) of 24-hour mean glucose. In this assessment, glucose levels were determined using continuous glucose monitoring (CGM) over 24 hours at Baseline and Day 13; CGM values were further corrected for blood glucose values obtained via participant-administered finger-stick. Least squares (LS) means values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.
Time frame: Baseline (Day -2) and Day 13
Change From Baseline in the Standard Deviation of Blood Glucose Levels
SD is a popular metric for assessment of postprandial glucose swings. The SD of all glycemic excursions over 24 hours (i.e., total of 288 glucose values over 24 hours) was determined for Baseline and Day 13. Original values were obtained using CGM and corrected for blood glucose values obtained via participant-administered finger-stick. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.
Time frame: Baseline (Day -2) and Day 13
Change From Baseline in Maximum Incremental Postprandial Glucose Levels in Each Meal
The peak postprandial glucose level during the 3 hours post meal minus the preprandial glucose level 1 hour before meal was determined for corrected CGM values at Baseline and Day 13 for breakfast, lunch, and dinner. Meals were standardized with respect to total calories, and protein, fat, and carbohydrate composition as well as timing of administration. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates better control of postprandial glucose.
Time frame: Baseline (Day -2) and Day 13
Change From Baseline in 24-hour Mean Glucose Level
The mean glucose level over 24-hours at Baseline and Day 13 was determined using CGM values corrected for participant-administered finger-stick values. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.
Time frame: Baseline (Day -2) and Day 13
Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)
Hypoglycemia, defined as low blood glucose, is a common side effect of medications used to treat diabetes mellitus type 2. The percentage of hypoglycemic corrected CGM readings (sensor glucose \<70, \<60, \<50 mg/dL) over a 24-hour period were determined at baseline and Day 13. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates improvement in occurrence of hypoglycemia.
Time frame: Baseline (Day -2) and Day 13
Screening for study inclusion was performed over a 4-week period. Adults with type 2 diabetes were randomized into the study.
| Milestone | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| Started | 26 | 27 |
| Treated | 26 | 26 |
| Completed | 26 | 26 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
MAGE is a popular metric for assessment of major (e.g., postprandial) glucose swings. MAGE is calculated as the average of differences between consecutive glucose peaks and nadirs greater than 1 standard deviation (SD) of 24-hour mean glucose. In this assessment, glucose levels were determined using continuous glucose monitoring (CGM) over 24 hours at Baseline and Day 13; CGM values were further corrected for blood glucose values obtained via participant-administered finger-stick. Least squares (LS) means values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.
| mg/dL | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13 | -18.5 (-30.0 to -7.1) | -9.7 (-21.1 to 1.6) |
SD is a popular metric for assessment of postprandial glucose swings. The SD of all glycemic excursions over 24 hours (i.e., total of 288 glucose values over 24 hours) was determined for Baseline and Day 13. Original values were obtained using CGM and corrected for blood glucose values obtained via participant-administered finger-stick. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.
| mg/dL | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| Change From Baseline in the Standard Deviation of Blood Glucose Levels | -10.2 (-14.4 to -6.0) | -4.2 (-8.4 to -0.1) |
The peak postprandial glucose level during the 3 hours post meal minus the preprandial glucose level 1 hour before meal was determined for corrected CGM values at Baseline and Day 13 for breakfast, lunch, and dinner. Meals were standardized with respect to total calories, and protein, fat, and carbohydrate composition as well as timing of administration. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates better control of postprandial glucose.
| mg/dL | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| Breakfast | -24.8 (-34.1 to -15.6) | -12.0 (-21.1 to -2.9) |
| Lunch | -13.2 (-24.0 to -2.3) | 1.2 (-9.6 to 11.9) |
| Dinner | -9.0 (-20.9 to 2.9) | -14.1 (-25.9 to -2.3) |
The mean glucose level over 24-hours at Baseline and Day 13 was determined using CGM values corrected for participant-administered finger-stick values. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.
| mg/dL | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| Change From Baseline in 24-hour Mean Glucose Level | -19.1 (-28.5 to -9.7) | -34.8 (-44.0 to -25.5) |
Hypoglycemia, defined as low blood glucose, is a common side effect of medications used to treat diabetes mellitus type 2. The percentage of hypoglycemic corrected CGM readings (sensor glucose \<70, \<60, \<50 mg/dL) over a 24-hour period were determined at baseline and Day 13. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates improvement in occurrence of hypoglycemia.
| Percent change | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| <70 mg/dL | -0.3 (-1.6 to 1.0) | 0.8 (-0.5 to 2.1) |
| <60 mg/dL | -0.4 (-1.3 to 0.5) | 0.2 (-0.7 to 1.1) |
| <50 mg/dL | -0.3 (-0.8 to 0.2) | -0.3 (-0.7 to 0.2) |
Collected over Up to 4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 50 mg | — | 0/26 (0%) | 11/26 (42.3%) |
| Glibenclamide 2.50 mg TDD | — | 0/26 (0%) | 10/26 (38.5%) |
| Event | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD |
|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 10/26 | 6/26 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/26 | 3/26 |
| PeriodontitisInfections and infestations | 2/26 | 0/26 |
| Dermatitis ContactSkin and subcutaneous tissue disorders | 0/26 | 2/26 |
| PruritisSkin and subcutaneous tissue disorders | 2/26 | 2/26 |
Baseline data is provided for the Full Analysis Set (FAS) population consisting of all randomized participants who received at least one dose of study treatment, with at least one post-randomization/post-treatment observation for analysis, and with applicable baseline data.
| Age, Continuous(Years) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Mean | 60.2 ± 8.4 | 59.5 ± 10.7 | 59.8 ± 9.5 |
| Age, Customized(Participants) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| <65 years | 15 | 16 | 31 |
| >=65 years | 11 | 10 | 21 |
| Sex: Female, Male(Participants) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 26 | 25 | 51 |
| Body Weight(kg) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Mean | 70.2 ± 8.2 | 70.7 ± 11.2 | 70.5 ± 9.7 |
| Height(cm) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Mean | 169.5 ± 5.4 | 169.3 ± 5.3 | 169.4 ± 5.3 |
| Body Mass Index(kg/m^2) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Mean | 24.4 ± 2.1 | 24.6 ± 3.0 | 24.5 ± 2.6 |
| Duration of Diabetes Mellitus(Years) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Mean | 6.4 ± 5.4 | 9.9 ± 5.5 | 8.2 ± 5.7 |
| Smoking Status(Participants) | Sitagliptin 50 mg | Glibenclamide 2.50 mg TDD | Total |
|---|---|---|---|
| Current Smoker | 8 | 9 | 17 |
| Ex-Smoker | 10 | 10 | 20 |
| Never Smoked | 8 | 7 | 15 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2015 to primary completion in Dec 2015, 10 months.
Results were first posted in Jan 2017, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin